《星岛》记者黄冬艳 广州报道近一年处于大甩卖节奏的药明系，近日却突然宣布要花数十亿吞下东曜药业。1月14日晚间，药明生物（02269.HK）、药明合联（02268.HK）及东曜药业（01875.HK）联合公告宣布，药明合联拟通过现金要约方式收购东曜药业全部已发行股份，作价合计约30.91亿港元（约合人民币27.62亿元），成为CXO行业开年首笔重大并购案。市场普遍认为，随着ADC（抗体偶联药物）...
Source Link《星岛》记者黄冬艳 广州报道近一年处于大甩卖节奏的药明系，近日却突然宣布要花数十亿吞下东曜药业。1月14日晚间，药明生物（02269.HK）、药明合联（02268.HK）及东曜药业（01875.HK）联合公告宣布，药明合联拟通过现金要约方式收购东曜药业全部已发行股份，作价合计约30.91亿港元（约合人民币27.62亿元），成为CXO行业开年首笔重大并购案。市场普遍认为，随着ADC（抗体偶联药物）...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.